High visceral fat percentage is associated with poor outcome in endometrial cancer
Metrics: HTML 990 views | ?
Karen Klepsland Mauland1,2, Øyvin Eng3, Sigmund Ytre-Hauge4,5, Ingvild L. Tangen1,2, Anna Berg1,2, Helga B. Salvesen1,2,*, Øyvind O. Salvesen6, Camilla Krakstad1,7, Jone Trovik1,2, Erling A. Hoivik1,2, Henrica Maria Johanna Werner1,2, Gunnar Mellgren3,8 and Ingfrid S. Haldorsen4,5
1Centre for Cancer Biomarkers, CCBIO, Department of Clinical Science (K2), University of Bergen, Bergen, Norway
2Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway
3Hormone Laboratory, Haukeland University Hospital, Bergen, Norway
4Department of Radiology, Haukeland University Hospital, Bergen, Norway
5Department of Clinical Medicine (K1), University of Bergen, Bergen, Norway
6Unit for Applied Clinical Research, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway
7Centre for Cancer Biomarkers, CCBIO, Department of Biomedicine, University of Bergen, Bergen, Norway
8KG Jebsen Centre for Diabetes Research, Department of Clinical Science (K2), University of Bergen, Bergen, Norway
Karen Klepsland Mauland, email: Karen.Mauland@uib.no
Ingfrid S. Haldorsen, email: Ingfrid.Haldorsen@uib.no
Keywords: endometrial cancer; obesity; visceral fat; hormone receptor expression; transcriptional profiling
Received: May 10, 2017 Accepted: September 03, 2017 Published: October 19, 2017
Despite evidence of increased endometrial cancer (EC) risk in obese women, the impact of obesity on clinical and histological phenotype is poorly understood. This study explored abdominal fat volumes and fat distribution quantified by computed tomography (CT), in relation to tumor characteristics and outcome. 227 EC patients with preoperative abdominal CT scans were included. Total abdominal fat volume (TAV), subcutaneous abdominal fat volume (SAV) and visceral abdominal fat volume (VAV) were quantified, and visceral fat percentage calculated (VAV%=[VAV/TAV]x100). Waist circumference (WC) and liver density (LD) were measured, and body mass index (BMI) calculated. Data for estrogen, progesterone and androgen receptor (ERα/PR/AR) expression by immunohistochemistry were available for 149 tumors, and global gene expression data for 105 tumors. High BMI, TAV, SAV, VAV and WC, and low LD, were associated with low grade endometrioid tumors and PR and AR positivity (all p≤0.03). High VAV% was associated with high age (p<0.001), aneuploidy (p=0.01) and independently predicted reduced disease-specific survival (HR 1.05, 95% CI 1.00-1.11, p=0.041). Tumors from patients with low VAV% showed enrichment of gene sets related to immune activation and inflammation. In conclusion, high VAV% independently predicts reduced EC survival. Tumors arising in patients with low VAV% show enrichment of immune and inflammation related gene sets, suggesting that the global metabolic setting may be important for tumor immune response.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.